Analysis of FAS (CD95) gene mutations in higher-grade transformation of follicle center lymphoma

Bao Do, Izidore S. Lossos, Yvonne Thorstenson, Peter J. Oefner, Ronald Levy

Research output: Contribution to journalReview articlepeer-review

9 Scopus citations


The FAS antigen (CD95/APO-1) is suggested to be a tumor suppressor gene since mice and patients with congenital FAS mutations are prone to B cell lymphomas and somatic FAS mutations are described in hematological and solid tumors. Indeed, mutations of the FAS antigen have been found in 13% of multiple myelomas, 6% of follicle center lymphomas (FCL) and 21% of diffuse large B-cell lymphomas (DLBCL). To assess the possible role of FAS mutations in higher-grade transformation of FCL, biopsy specimens from 16 FCL patients were analyzed by denaturing high performance liquid chromatography and direct sequencing. Overall, 17 biopsy specimens obtained at the time of FCL diagnosis (2 biopsy specimens from one patient), 4 sequential biopsies obtained at the time of FCL relapse and 14 sequential biopsies from the time of morphologic transformation to DLBCL were evaluated. Ten polymorphisms were detected, only 4 of which have been reported previously. Nine of the polymorphisms occurred in non-translated regions, while one silent mutation was located in exon 7. Neither loss of heterozygosity nor occurrence of new mutations was observed upon higher-grade transformation of FCL to DLBCL.

Original languageEnglish (US)
Pages (from-to)1317-1323
Number of pages7
JournalLeukemia and Lymphoma
Issue number8
StatePublished - Aug 1 2003
Externally publishedYes


  • FAS(CD95)
  • Follicle center lymphoma
  • Gene mutations
  • Mutations
  • Transformation

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Analysis of FAS (CD95) gene mutations in higher-grade transformation of follicle center lymphoma'. Together they form a unique fingerprint.

Cite this